TruTYPE® — KNOW
Estimates the patient's functional PK state from the combined genetic, medication and relevant patient context.
TRUTYPE®
Functional Pharmacokinetic Intelligence
Because Genotype Is Only the Beginning.
A genotype is static. The medication regimen, age and disease progression are not. TruTYPE places inherited information in the context of the patient's current and considered medications, inhibitors, inducers and other relevant factors to estimate the functional pharmacokinetic state providers can evaluate now.
The core concept: inherited genetics provides a starting point. TruTYPE adds the changing medication and patient environment to estimate the functional PK context across CYP enzymes and transporters.
Illustrative medication examples are provided to explain pharmacokinetic concepts and are not treatment recommendations. Patient-specific information is provided for licensed healthcare providers to evaluate.
AUTOMATED PHENOCONVERSION
The genotype stays the same. The highway conditions can change.
See how medication-driven pathway effects can change the functional pharmacokinetic picture even while inherited genetics remains unchanged.
WHAT TRUTYPE CONNECTS
Build the patient's functional PK picture.
Select each input to see what it contributes. PGx is an important input when available—not the entire picture.
PGx / GENOTYPE
The static starting point
When PGx results are available, inherited function can establish a baseline for relevant pharmacokinetic pathways. When PGx has not been tested, the model can begin from a clearly identified default-normal assumption rather than treating it as a measured result.
THE INTELLIGENCE CONTINUUM
Know the functional state. Prioritize what matters. Evaluate options.
TruRISK® — PRIORITIZE
Uses that exposure context to identify and prioritize medications with the most relevant current exposure concerns for provider review.
TruSELECT® — EVALUATE
Evaluates considered medications in the context of the patient's current functional PK environment.
PATENTED TECHNOLOGY
U.S. Patent No. 11,965,206
The TruTYPE intellectual-property foundation includes patented methods involving adjusted phenotypes of drug-metabolizing enzymes in multi-drug therapy. Patent status describes the intellectual property and is not presented as proof of clinical effectiveness.
From TruTYPE to TruRISK.
Once the functional PK picture is established, the next question is which medication risks matter most for this patient now.